@article{edcf5693b25248e9bac367ab59dfb1f9,
title = "Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis treatment and follow-up of patients with localised colon cancer",
abstract = "The most recent version of the European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for the diagnosis, treatment and follow-up of localised colon cancer was published in 2020. It was decided by both the ESMO and the Japanese Society of Medical Oncology (JSMO) to convene a special virtual guidelines meeting in March 2021 to adapt the ESMO 2020 guidelines to take into account the ethnic differences associated with the treatment of localised colon cancer in Asian patients. These guidelines represent the consensus opinions reached by experts in the treatment of patients with localised colon cancer representing the oncological societies of Japan (JSMO), China (CSCO), India (ISMPO), Korea (KSMO), Malaysia (MOS), Singapore (SSO) and Taiwan (TOS). The voting was based on scientific evidence and was independent of the current treatment practices and drug availability and reimbursement situations in the different Asian countries.",
author = "T. Yoshino and G. Argil{\'e}s and E. Oki and E. Martinelli and H. Taniguchi and D. Arnold and S. Mishima and Y. Li and Smruti, {B. K.} and Ahn, {J. B.} and I. Faud and Chee, {C. E.} and Yeh, {K. H.} and Lin, {P. C.} and C. Chua and Hasbullah, {H. H.} and Lee, {M. A.} and A. Sharma and Y. Sun and G. Curigliano and H. Bando and F. Lordick and T. Yamanaka and J. Tabernero and E. Baba and A. Cervantes and A. Ohtsu and S. Peters and C. Ishioka and G. Pentheroudakis",
note = "Funding Information: All costs relating to this consensus conference were covered by the JSMO central dedicated funds (no grant number is applicable). There was no external funding of the event or the manuscript production. Funding Information: The authors would like to thank Ms C. Tada from the Secretariat of JSMO, Ms K. Marinoni, Ms Z. Othman, Ms D. Young and Dr A. Meredith Garcia from the Scientific and Medical Division of ESMO, and Ms K. Oiwa, Ms K. Edwards and Mr M. Ono of the IT vendor PEAK-1 for their assistance in the execution of the ?face-to-face? virtual meeting of experts. Dr A. Kinsella of Cancer Communications and Consultancy Ltd, Knutsford, Cheshire, UK, is acknowledged for her contribution in the preparation of the manuscript. All costs relating to this consensus conference were covered by the JSMO central dedicated funds (no grant number is applicable). There was no external funding of the event or the manuscript production. TY has reported research funding from Taiho Pharmaceuticals, Sumitomo Dainippon Pharma Co. Ltd, Chugai Pharmaceutical Co. Ltd, Sanofi KK, Daiichi Sankyo Co. Ltd, Parexel International Inc. and ONO Pharmaceutical Co. Ltd. GA has reported that he has acted as a consultant or speaker for Amgen, Roche, Merck, Sanofi, Servier, Merck Sharp & Dohme and Bayer. EO has declared fees for consultancy, speaking and advisory roles from Eli Lilly, Taiho Pharmaceuticals, Chugai Pharmaceutical Co. Ltd. Takeda, Pharmaceuticals, ONO Pharmaceutical Co. Ltd. Bayer and Bristol-Myers Squibb. EM has received honoraria for lecture and advisory boards from Roche, Amgen, Servier, AstraZeneca, Bayer, Merck Serono, Pierre Fabre, Incyte and Sanofi and speaker support from ESMO. HT declares research funding from RDKK, Sysmex, Daiichi Sankyo, Taiho and Takeda. DA has acted as a consultant or speaker for ACE Oncology, Amgen, Aptitude Health, art tempi media, AstraZeneca, Bayer, Boston Scientific, Bristol-Myers Squibb, CCO, CRA International, Eli Lilly, From Research to Practice, Hexal, Imedex, Ipsen, IQIVIA, Ketchum, MedAhead (Austria), Merck Serono, Merck Sharp and Dohme, Oncolytics, PharmaCept, Pierre Fabre, PRIMA Consulting, Roche, Samsung Bioepsis, Sanofi (Genyme), Terumo and Servier; received fees from Elsevier, WebHealth and Oxford University Press; and institutional funding from Bristol-Myers Squibb, OncoLytics and Pierre Fabre. BKS declares fees for consultancy and advisory roles from Eli Lilly, Novartis, Pfizer, AstraZeneca and Boehringer Ingelheim. IF declares fees for consultancy and advisory roles from Roche, AstraZeneca, Pfizer Merck and Novartis and research funding from Genetech, Samsung and Boehringer Ingelheim. K-HY declares fees for consultancy and advisory roles from Amgen, Boehringer Ingelheim, Bayer, Bristol-Myers Squibb, Merck Serono, Eli Lilly, ONO Pharmaceuticals, Takeda, Merck Sharp and Dohme, Daiichi Sankyo and AstraZeneca. GC declares fees for consultancy and advisory roles from AstraZeneca, Daichii Sankyo, Bristol-Myers Squibb, Lilly, Pfizer, Novartis, Ellipsis, Merck and Seagen. HB declares fees for consultancy and advisory roles from Eli Lilly, Taiho Pharmaceuticals and ONO Pharmaceutical Co. Ltd. FL declares fees for consultancy, speaking and advisory roles from Amgen, Astellas, AstraZeneca, Bayer, Beigene, Bristol-Myers Squibb, Eli Lilly, Imedex, MedUpdate, Merck Serono, Merck Sharp and Dohme, Promedicis, Roche, Servier, StreamedUp and Zymeworks; writing fees from Deutscher Arzteverleg, Imedico and Springer-Nature; expert testimony fees from Biontech and Elsevier; and research funding from Bristol-Myers Squibb. TY declares research funding from Chugai, Bayer and Taiho. JT reports personal financial interest in the form of scientific consultancy roles for Array Biopharma, AstraZeneca, Avvinity, Bayer, Boehringer Ingelheim, Chugai, Daiichi Sankyo, F. Hoffmann-La Roche Ltd, Genentech Inc, HalioDX SAS, Hutchison MediPharma International, Ikena Oncology, IQVIA, Lilly, Menarini, Merck Serono, Merus, Merck Sharp and Dohme, Mirati, Neophore, Novartis, Orion Biotechnology, Peptomyc, Pfizer, Pierre Fabre, Samsung Bioepis, Sanofi, Seattle Genetics, Servier, Taiho, Tessa Therapeutics and TheraMyc; and educational collaborations with Imedex, Medscape Education, MJH Life Sciences, PeerView Institute for Medical Education and Physicians Education Resource (PER). EB declares research funding from Bristol-Myers Squibb, Merck Sharp & Dohme, Eisai, Taiho, Bayer, Eli Lilly and Daichi-Sankyo. AC has reported fees for consultancy and advisory roles from Merck Serono, Amgen, BeiGene and Bristol-Myers Squibb; and research funding from AbbVie, Actuate Therapeutics, Alkermes Inc, Amgen, Astellas Pharma, Beigene, Bioncotech Therapeutics, Boehringer Ingelheim, Debiopharm International, F. Hoffmann-La Roche, FibroGen, Genmab, Janssen Research & Development, MedImmune, Meranini Ricerche, Novartis, Puma Biotechnology, Symphogen, Tahio, Transgene and WNT Research. AO has received research funding from Bristol-Myers Squibb. SP has reported fees for consultancy/advisory roles from AbbVie, Amgen, AstraZeneca, Bayer, Beigene, Biocartis, Boehringer Ingelheim, Bristol-Myers Squibb, Clovis, Daiichi Sankyo, Debiopharm, ecancer, Eli Lilly, Elsevier, Foundation Medicine, Illumina, Imedex, Incyte, Janssen, Medscape, Merck Sharp and Dohme, Merck Serono, Merrimack, Novartis, Pharma Mar, Phosplatin Therapeutics, PER, Pfizer, PRIME, Regeneron, Roche/Genentech, RTP, Sanofi, Seattle Genetics and Takeda; speaker roles for AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, ecancer, Eli Lilly, Illumina, Imedex, Medscape, Merck Sharp and Dohme, Novartis, PER, Pfizer, Prime, Roche/Genentech, RTP, Sanofi and Takeda; and the receipt of grants/research support: (sub)investigator in trials (institutional financial support for trials) sponsored by Amgen, AstraZeneca, Biodesix, Boehringer Ingelheim, Bristol-Myers Squibb, Clovis, GSK, Illumina, Lilly, Merck Sharp and Dohme, Merck Serono, Mirati, Novartis, Pfizer, Phosplatin Therapeutics and Roche/Genentech. CI has received research funding from Chugai, Taiho, Daiichi-Sankyo, Takeda, Shionogi, Novartis, Eisai, Sanofi, Yakult, Merck Serono, Ono, Kyowa-Kirin, Nippon-Kayaku and Eli Lilly. GP reports fees for consultancy/advisory roles from Amgen, AstraZeneca, Bristol-Myers Squibb, Lilly, Merck, Merck Sharp and Dohme and Roche; and institutional funding from AbbVie, Amgen, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Debiopharm, Enorasis, Genekor, Ipsen, Janssen, Lilly, Merck, Merck Sharp and Dohme, Pfizer, Roche, Sanofi and Servier. The remaining authors have declared no conflicts of interest Publisher Copyright: {\textcopyright} 2021",
year = "2021",
month = dec,
doi = "10.1016/j.annonc.2021.08.1752",
language = "English",
volume = "32",
pages = "1496--1510",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "Oxford University Press",
number = "12",
}
